Low blood levels of long-chain n-3 polyunsaturated fatty acids in US hemodialysis patients: Clinical implications

Allon Friedman, Zhangsheng Yu, Rebeka Tabbey, Cheryl Denski, Hector Tamez, Julia Wenger, Ravi Thadhani, Yong Li, Bruce A. Watkins

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Cardioprotective and other clinical benefits of long-chain n-3 polyunsaturated fatty acids (PUFA) are inversely related to dietary intake and hence blood content. We therefore investigated, in the first study of its kind, the blood content and distribution of these fatty acids in a large representative population of US hemodialysis patients. Methods: Frozen sera were obtained from 400 individuals who were part of a large, contemporary, representative cohort of US incident hemodialysis patients. Long-chain n-3 PUFA were measured in total serum lipids and in the neutral and polar serum fractions using gas chromatography and solid phase extraction techniques. Mean long-chain n-3 PUFA levels were compared to levels in other dialysis and nondialysis populations from published reports. Results: The study population was qualitatively similar to the overall US hemodialysis population in terms of major clinical characteristics. Long-chain n-3 PUFA were present in the serum polar fraction, with essentially none being detected in the neutral fraction (p < 0.0001 for polar vs. neutral fractions for all three long-chain n-3 PUFA). Mean serum long-chain n-3 PUFA levels (weight percent (±SD): total 1.55 ± 0.95, polar 3.99 ± 1.45) were low compared to nondialysis and most other non-US hemodialysis cohorts. Conclusions: While US hemodialysis patients have a blood distribution of long-chain n-3 PUFA that is similar to that in the general population, blood content is among the lowest recorded in the medical literature. This has implications for renal dietary recommendations and makes US patients an ideal group for testing the clinical effects of long-chain n-3 PUFA supplementation.

Original languageEnglish
Pages (from-to)451-458
Number of pages8
JournalAmerican Journal of Nephrology
Volume36
Issue number5
DOIs
StatePublished - Nov 2012

Fingerprint

Omega-3 Fatty Acids
Renal Dialysis
Serum
Population
Solid Phase Extraction
Gas Chromatography
Dialysis
Fatty Acids
Kidney
Lipids
Weights and Measures

Keywords

  • Cardiovascular
  • Fatty acids
  • Hemodialysis
  • Nutrition
  • Omega-3

ASJC Scopus subject areas

  • Nephrology

Cite this

Low blood levels of long-chain n-3 polyunsaturated fatty acids in US hemodialysis patients : Clinical implications. / Friedman, Allon; Yu, Zhangsheng; Tabbey, Rebeka; Denski, Cheryl; Tamez, Hector; Wenger, Julia; Thadhani, Ravi; Li, Yong; Watkins, Bruce A.

In: American Journal of Nephrology, Vol. 36, No. 5, 11.2012, p. 451-458.

Research output: Contribution to journalArticle

Friedman, Allon ; Yu, Zhangsheng ; Tabbey, Rebeka ; Denski, Cheryl ; Tamez, Hector ; Wenger, Julia ; Thadhani, Ravi ; Li, Yong ; Watkins, Bruce A. / Low blood levels of long-chain n-3 polyunsaturated fatty acids in US hemodialysis patients : Clinical implications. In: American Journal of Nephrology. 2012 ; Vol. 36, No. 5. pp. 451-458.
@article{7e1f8e81bb8545dc99ffd044cd2289f4,
title = "Low blood levels of long-chain n-3 polyunsaturated fatty acids in US hemodialysis patients: Clinical implications",
abstract = "Background: Cardioprotective and other clinical benefits of long-chain n-3 polyunsaturated fatty acids (PUFA) are inversely related to dietary intake and hence blood content. We therefore investigated, in the first study of its kind, the blood content and distribution of these fatty acids in a large representative population of US hemodialysis patients. Methods: Frozen sera were obtained from 400 individuals who were part of a large, contemporary, representative cohort of US incident hemodialysis patients. Long-chain n-3 PUFA were measured in total serum lipids and in the neutral and polar serum fractions using gas chromatography and solid phase extraction techniques. Mean long-chain n-3 PUFA levels were compared to levels in other dialysis and nondialysis populations from published reports. Results: The study population was qualitatively similar to the overall US hemodialysis population in terms of major clinical characteristics. Long-chain n-3 PUFA were present in the serum polar fraction, with essentially none being detected in the neutral fraction (p < 0.0001 for polar vs. neutral fractions for all three long-chain n-3 PUFA). Mean serum long-chain n-3 PUFA levels (weight percent (±SD): total 1.55 ± 0.95, polar 3.99 ± 1.45) were low compared to nondialysis and most other non-US hemodialysis cohorts. Conclusions: While US hemodialysis patients have a blood distribution of long-chain n-3 PUFA that is similar to that in the general population, blood content is among the lowest recorded in the medical literature. This has implications for renal dietary recommendations and makes US patients an ideal group for testing the clinical effects of long-chain n-3 PUFA supplementation.",
keywords = "Cardiovascular, Fatty acids, Hemodialysis, Nutrition, Omega-3",
author = "Allon Friedman and Zhangsheng Yu and Rebeka Tabbey and Cheryl Denski and Hector Tamez and Julia Wenger and Ravi Thadhani and Yong Li and Watkins, {Bruce A.}",
year = "2012",
month = "11",
doi = "10.1159/000343741",
language = "English",
volume = "36",
pages = "451--458",
journal = "American Journal of Nephrology",
issn = "0250-8095",
publisher = "S. Karger AG",
number = "5",

}

TY - JOUR

T1 - Low blood levels of long-chain n-3 polyunsaturated fatty acids in US hemodialysis patients

T2 - Clinical implications

AU - Friedman, Allon

AU - Yu, Zhangsheng

AU - Tabbey, Rebeka

AU - Denski, Cheryl

AU - Tamez, Hector

AU - Wenger, Julia

AU - Thadhani, Ravi

AU - Li, Yong

AU - Watkins, Bruce A.

PY - 2012/11

Y1 - 2012/11

N2 - Background: Cardioprotective and other clinical benefits of long-chain n-3 polyunsaturated fatty acids (PUFA) are inversely related to dietary intake and hence blood content. We therefore investigated, in the first study of its kind, the blood content and distribution of these fatty acids in a large representative population of US hemodialysis patients. Methods: Frozen sera were obtained from 400 individuals who were part of a large, contemporary, representative cohort of US incident hemodialysis patients. Long-chain n-3 PUFA were measured in total serum lipids and in the neutral and polar serum fractions using gas chromatography and solid phase extraction techniques. Mean long-chain n-3 PUFA levels were compared to levels in other dialysis and nondialysis populations from published reports. Results: The study population was qualitatively similar to the overall US hemodialysis population in terms of major clinical characteristics. Long-chain n-3 PUFA were present in the serum polar fraction, with essentially none being detected in the neutral fraction (p < 0.0001 for polar vs. neutral fractions for all three long-chain n-3 PUFA). Mean serum long-chain n-3 PUFA levels (weight percent (±SD): total 1.55 ± 0.95, polar 3.99 ± 1.45) were low compared to nondialysis and most other non-US hemodialysis cohorts. Conclusions: While US hemodialysis patients have a blood distribution of long-chain n-3 PUFA that is similar to that in the general population, blood content is among the lowest recorded in the medical literature. This has implications for renal dietary recommendations and makes US patients an ideal group for testing the clinical effects of long-chain n-3 PUFA supplementation.

AB - Background: Cardioprotective and other clinical benefits of long-chain n-3 polyunsaturated fatty acids (PUFA) are inversely related to dietary intake and hence blood content. We therefore investigated, in the first study of its kind, the blood content and distribution of these fatty acids in a large representative population of US hemodialysis patients. Methods: Frozen sera were obtained from 400 individuals who were part of a large, contemporary, representative cohort of US incident hemodialysis patients. Long-chain n-3 PUFA were measured in total serum lipids and in the neutral and polar serum fractions using gas chromatography and solid phase extraction techniques. Mean long-chain n-3 PUFA levels were compared to levels in other dialysis and nondialysis populations from published reports. Results: The study population was qualitatively similar to the overall US hemodialysis population in terms of major clinical characteristics. Long-chain n-3 PUFA were present in the serum polar fraction, with essentially none being detected in the neutral fraction (p < 0.0001 for polar vs. neutral fractions for all three long-chain n-3 PUFA). Mean serum long-chain n-3 PUFA levels (weight percent (±SD): total 1.55 ± 0.95, polar 3.99 ± 1.45) were low compared to nondialysis and most other non-US hemodialysis cohorts. Conclusions: While US hemodialysis patients have a blood distribution of long-chain n-3 PUFA that is similar to that in the general population, blood content is among the lowest recorded in the medical literature. This has implications for renal dietary recommendations and makes US patients an ideal group for testing the clinical effects of long-chain n-3 PUFA supplementation.

KW - Cardiovascular

KW - Fatty acids

KW - Hemodialysis

KW - Nutrition

KW - Omega-3

UR - http://www.scopus.com/inward/record.url?scp=84868228886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868228886&partnerID=8YFLogxK

U2 - 10.1159/000343741

DO - 10.1159/000343741

M3 - Article

C2 - 23128302

AN - SCOPUS:84868228886

VL - 36

SP - 451

EP - 458

JO - American Journal of Nephrology

JF - American Journal of Nephrology

SN - 0250-8095

IS - 5

ER -